Browse News by Year:
News Highlights:
July 15, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical,biotechnology, and medical device industries, with operations in China and the United States, today announced its preliminary financial highlights for second-quarter 2010. The full earnings results will be
announced on August 2, 2010. View Full Article
announced on August 2, 2010. View Full Article
July 14, 2010 - EnVivo Pharmaceuticals today announced at the Alzheimer’s Association 2010 International Conference on Alzheimer’s Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. View Full Article
Accuri Cytometers Completes $6 Million Series E Financing
July 12, 2010 - Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. View Full Article
June 30, 2010 - Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced today that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences. Proceeds from the financing will be used to fund Phase I and II development of V-101, the company’s lead investigational product for the treatment of rosacea, as well as a second product to treat various forms of bruising and purpura. View Full Article
Ikano Therapeutics in Exclusive Global Licensing Agreement for ITI-111
June 28, 2010 - Ikano Therapeutics Inc. (ITI) and Upsher-Smith Laboratories, Inc. announced today that they have concluded an exclusive global licensing agreement for ITI-111, ITI’s midazolam nasal spray. Under the terms of the agreement, Upsher-Smith will assume responsibility for all further development and commercialization of the product, which has received Orphan Drug status for the treatment of acute repetitive seizures in patients with epilepsy. View Full Article
Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology
June 23, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana’s Fleximer® platform. Mersana’s XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Phase 1 study. View Full Article
June 17, 2010 - Transave announces positive Phase II results for once-daily ARIKACE™ in the treatment of cystic fibrosis patients who have pseudomonas lung infections, View Full Article
FoldRx Pharmaceuticals Secures $29 Million Financing
June 15, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced it has closed a $29 million financing to advance tafamidis to market. FoldRx has completed and previously reported the positive results of a pivotal trial of tafamidis as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening genetic neurodegenerative disease that affects thousands of patients worldwide. New investors Novo Ventures and Morgenthaler Ventures join existing investors HealthCare Ventures, Fidelity Biosciences, TPG Biotechnology, Alta Partners, and Novartis Venture Funds. View Full Article
Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus
June 1, 2010 - Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. View Full Article
Tetraphase Closes $45 Million Series C Financing
June 1, 2010 - Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing. Excel Venture Management led the round with participation from existing investors CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures. View Full Article
Transave Issues Key Composition of Matter Patent for Arikace (TM)
May 24, 2010 - Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE™ until October 1, 2026. View Full Article
NeuroTherapeutics Pharma Closes $43 Million Series B Financing and Adds Four New Investors
May 20, 2010 - NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co‐led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round. View Full Article
WuXi PharmaTech Announces First-Quarter 2010 Results
May 12, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for first-quarter 2010. View Full Article
Envivo Initiates Phase IIB Alzheimer's Disease Trial for EVP-6124
May 11, 2010 - EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer’s disease. The multi-center, dose ranging, placebo controlled, six-month study taking place in the U.S. and Europe is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer’s disease patients. View Full Article
Ironwood Pharmaceuticals Provides First Quarter 2010 Investor Update
May 11, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its business activities for the first quarter of 2010. View Full Article
Accuri and eBioscience Partner to Offer Complete Flow Cytometry Solutions
May 10, 2010 - Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement. The collaboration is designed to offer scientists a better and more comprehensive solution for their flow cytometry research needs, harnessing the cost-effectiveness, ease-of-use, performance capabilities and accessibility of the Accuri C6 Flow Cytometer® System with the market leading extensive line of high quality cytometer research reagents offered by eBioscience. View Full Article
FoldRx Pharmaceuticals Appoints Dr. Georges Gemayel as Executive Chairman
May 5, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that Georges Gemayel, Ph.D., has been appointed full time Executive Chairman of the company’s Board of Directors. Dr. Gemayel brings to the role more than 25 years of experience in successfully developing and commercializing drugs with several notable pharmaceutical and biotechnology companies. View Full Article
May 3, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today presented Phase 3 clinical trial results assessing the efficacy and safety of the investigational drug linaclotide in patients with chronic constipation (CC). Linaclotide is a guanylate cyclase type C (GC‐C) agonist in Phase 3 clinical development for the treatment of irritable bowel syndrome with constipation (IBS‐C) and CC. The data presented demonstrate that statistical significance versus placebo was achieved for the primary endpoint of 12‐week complete spontaneous bowel movement (CSBM) overall responder for each of the two doses studied in each trial. View Full Article
April 29, 2010 - Tetraphase Pharmaceuticals Inc., a biopharmaceutical company developing novel antibiotics based on proprietary synthetic chemistry technology, today announced that it will be participating in a session on drug discovery and development of novel treatments for drug-resistant infections, taking place at the 2010 BIO International Convention in Chicago. View Full Article
April 28, 2010 - LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010. View Full Article
April 26, 2010 - Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion. View Full Article
FoldRx Pharmaceuticals Presents at the XII International Symposium on Amyloidosis Meeting
April 21, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers presented results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the XII International Symposium on Amyloidosis in Rome, Italy. Tafamidis, the company’s lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide. View Full Article
April 20, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010. View Full Article
FoldRx Pharmaceuticals to Present at the American Academy of Neurology (AAN) Annual Meeting
April 14, 2010 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers will present results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the 62nd American Academy of Neurology (AAN) Annual Meeting in Toronto. Tafamidis, the company’s lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide. View Full Article
April 13, 2010 - Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has entered into a research and exclusive license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize XMT-1107, a novel fumagillin analog, for the treatment of all indications, including cancer. Mersana plans to initiate a Phase 1 clinical trial for XMT-1107 in the second quarter of 2010. XMT-1107 will be the company’s second oncology product to enter the clinic. Mersana’s XMT-1001, a conjugate of Fleximer and camptothecin (CPT), is currently completing a Phase 1 study. View Full Article
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
March 9, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2009.
View Full Article
View Full Article
March 1, 2010 - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.
Underwriters Exercise Over-Allotment Option for Ironwood Pharmaceuticals' Initial Public Offering
February 16, 2010 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its February 2, 2010 initial public offering (IPO) have exercised their over-allotment option in full on an additional 2.5 million shares of Ironwood’s Class A common stock. View Full Article
ViewRay Wins NorTech Innovation Award
February 16, 2010 - ViewRay, Inc., a privately held medical device company, has earned a NorTech Innovation Award for its advancements in radiation therapy technology for the treatment of cancer. ViewRay was honored for its unique combination of medical imaging and radiotherapy, which is designed to improve the effectiveness of cancer treatments. Radiation therapy is used to treat nearly two‐thirds of today’s cancer patients. View Full Article
January 19, 2010 - EnVivo Pharmaceuticals, Inc. has been awarded a research grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund research as part of the foundation’s Therapeutics Development Initiative that seeks new treatments for Parkinson’s disease. View Full Article
EnVivo Enters Phase 2B Trials for its EVP-6124 Compound in the Treatment of Schizophrenia
January 5, 2010 - EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe. View Full Article
Ironwood Pharmaceuticals Files Registration Statement for Initial Public Offering
November 20, 2009 - Ironwood Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the offering have not yet been determined. View Full Article
Ikano Therapeutics Receives Orphan Drug Designation for Epilepsy Drug
November 9, 2009 - Ikano Therapeutics, Inc. (ITI) announced today that it has received orphan drug designation for midazolam in the acute treatment of certain forms of epileptic seizure known as cluster seizures or alternatively, as acute repetitive seizures. ITI has a nasally administered form of midazolam called ITI-111 in late stage clinical development that is aimed at the treatment of these specific seizure types in an outpatient setting where other routes of administration can be difficult or inappropriate. Orphan Drug status confers seven years of marketing exclusivity for medicines that meet specific criteria in the treatment of qualifying conditions and patient populations. View Full Article
Bioconnect Systems to Present First in Man Results for Optiflow™ Vascular Implant
October 27, 2009 - Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN
Meeting in San Diego. Bioconnect’s implant platform, the Optiflow™, enhances a surgeon’s ability to create precise vascular connections. The initial indication is the creation
of an arteriovenous fistula needed for vascular access in dialysis patients. View Full Article
Meeting in San Diego. Bioconnect’s implant platform, the Optiflow™, enhances a surgeon’s ability to create precise vascular connections. The initial indication is the creation
of an arteriovenous fistula needed for vascular access in dialysis patients. View Full Article
October 17, 2009 - Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. The latest results along with previously reported data demonstrate significant clinical benefits and complete the company’s Phase II program in two indications – for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients and non-CF bronchiectasis patients. View Full Article
September 10, 2009 - Tetraphase Pharmaceuticals Inc., a
biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology
announced today that it will present three (3) posters and deliver a slide presentation on
the synthesis and antibacterial activity of analogs from several novel classes of antibiotics
to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC) in San Francisco, CA. View Full Article
biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology
announced today that it will present three (3) posters and deliver a slide presentation on
the synthesis and antibacterial activity of analogs from several novel classes of antibiotics
to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC) in San Francisco, CA. View Full Article
July 29, 2009 - Transave Inc. announced today that it has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to study ARIKACE™ (liposomal amikacin for inhalation) in patients with nontuberculous mycobacteria (NTM) lung infections. View Full Article
AccuriCytometers Completes $4 Million Series D Financing
July 13, 2009 - Accuri Cytometers, Inc. today announced the completion of a $4
million Series D financing. The financing included current investors Fidelity Biosciences, Flagship
Ventures, Baird Venture Partners and Arboretum Ventures, as well as the InvestMichigan! Program comanaged
by Credit Suisse. Accuri will use the proceeds from the Series D financing to provide additional
working and growth capital to support the rapid market acceptance of the Accuri C6 Flow Cytometer®
System, a revolutionary product designed to bring the power of flow cytometry analysis to the laboratory
of every life science researcher, and the recently introduced Accuri CSampler™, an optional accessory
that adds user-friendly automation to the C6 system. View Full Article
million Series D financing. The financing included current investors Fidelity Biosciences, Flagship
Ventures, Baird Venture Partners and Arboretum Ventures, as well as the InvestMichigan! Program comanaged
by Credit Suisse. Accuri will use the proceeds from the Series D financing to provide additional
working and growth capital to support the rapid market acceptance of the Accuri C6 Flow Cytometer®
System, a revolutionary product designed to bring the power of flow cytometry analysis to the laboratory
of every life science researcher, and the recently introduced Accuri CSampler™, an optional accessory
that adds user-friendly automation to the C6 system. View Full Article
Transave Completes Enrollment In ARIKACE™ Phase II Bronchiectasis Study
April 21, 2009 - Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace™ (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the disease. View Full Article
ViewRay Incorporated Closes $15M Tranche of Series B Financing
April 14, 2009 - ViewRay Incorporated, a
medical device company, announces the close of the second tranche of their $25M Series
B financing. Funding was triggered by the company’s achievement of a major milestone
towards the development of their image guided cancer therapy device, the Renaissance™
System. The financing was led by OrbiMed Advisors and Fidelity Biosciences, and was
joined by Aisling Capital and Kearny Venture Partners. View Full Article
medical device company, announces the close of the second tranche of their $25M Series
B financing. Funding was triggered by the company’s achievement of a major milestone
towards the development of their image guided cancer therapy device, the Renaissance™
System. The financing was led by OrbiMed Advisors and Fidelity Biosciences, and was
joined by Aisling Capital and Kearny Venture Partners. View Full Article
October 6, 2008 - View Full Article
August 25, 2008 - Proteostasis Therapeutics, Inc. (PTI) today announced that it has secured $45 million in a Series A financing led by Fidelity Biosciences. View Full Article
ProteoStasis Therapeutics: Cultivating the next Big Idea company
August 24, 2008 - Boston.com discusses Fidelity Biosciences' recent investment in ProteoStasis Therapeutics. View Full Article
WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
August 1, 2008 - August 1, 2008 – Shanghai, China – WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has appointed Mr. Steven M. Hutchins as Vice President of Business Development. View Full Article
July 16, 2008 - U.S. Genomics today announced the award of a $9.1 million contract by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate. View Full Article
Accuri Cytometers Completes $13 Million Series C Financing
July 8, 2008 - Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a $13 million Series C financing led by Fidelity Biosciences and Flagship Ventures. View Full Article
FoldRx Technology Enables Discovery of Novel Therapeutic Approach for Treating Cystic Fibrosis
July 8, 2008 - FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that it has discovered a series of novel drug prototypes that have shown potential in vitro to correct the protein-folding defect associated with cystic fibrosis (CF). View Full Article
Intranasal Therapeutics Names Jeffrey Edelson, MD,
July 8, 2008 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced a key executive addition to the company’s leadership team. Jeff Edelson, MD, previously employed by Johnson & Johnson (J&J) as Vice President, Internal Medicine and Therapeutic Area Head - Novel Therapeutics, has joined ITI as Executive Vice President, R&D, and Chief Medical Officer. View Full Article
Accuri Cytometers Inc. to Distribute FCS Express
June 27, 2008 - De Novo Software, a leading provider of flow cytometry data analysis solutions, and Accuri Cytometers, a privately held manufacturer of innovative benchtop flow cytometry systems, announced today that they have entered into a licensing agreement providing for Accuri to distribute a customized version of De Novo Software's flagship product, FCS Express, with every Accuri C6 Flow Cytometer System. View Full Article
June 13, 2008 - Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace™ (liposomal amikacin for inhalation). The compound is being developed for the treatment of cystic fibrosis (CF) patients who have lung infections... View Full Article
U.S. Genomics Recognized for Outstanding Entrepreneurship
June 12, 2008 - U.S. Genomics Inc, a pioneer of single molecule biology technologies for the biodefense and life sciences industries, has been recognized by the NSF for outstanding entrepreneurship at its May NSF SBIR /STTR (Small Business Innovation Research/Small Business Technology Transfer) Phase II Grantee Conference. View Full Article
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
February 12, 2008 - Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer. View Full Article
Methygene Exercises Right to Opt-Out of HDAC Neurodegenerative Collaboration with Envivo
February 6, 2008 - MethylGene Inc. (TSX:MYG) and EnVivo Pharmaceuticals today announced that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005. EnVivo will continue to research and develop... View Full Article
Dr. Manuel Worcel Appointed CEO and President of Cardiokine
January 22, 2008 - Cardiokine, Inc., a privately held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, today announced that Dr. Manuel Worcel has been appointed President and Chief Executive Officer. View Full Article
ViewRay Incorporated Raises $25 Million in Series B Financing
January 21, 2008 - ViewRay Incorporated (http://www.viewray.com/), a medical device manufacturer, announced today the close of a $25 million Series B financing. Founded in 2004, ViewRay Incorporated is focused on the development of a real-time magnetic resonance imaging (MRI)... View Full Article
Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
January 3, 2008 - Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company’s Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career. View Full Article
December 14, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts... View Full Article
Governor Patrick Highlights Progress on the Massachusetts-China Relationship
December 10, 2007 - Governor Deval Patrick today highlighted progress made on the Massachusetts-China relationship during the Commonwealth’s first governor-led trade mission to China in seven years, including agreements signed between life science and clean energy groups... View Full Article
$22 Million to Help Acorn Fund Heart Device
December 9, 2007 - A small New Brighton company that has developed a unique device to treat patients who have heart failure said Wednesday that it has secured $22 million in financing. View Full Article
Topaz Pharmaceuticals Receives $20 Million Series A Financing
December 3, 2007 - (HSMN NewsFeed)--Topaz Pharmaceuticals Inc., a pharmaceutical company dedicated to the health and well being of children, today announced that it has secured $20 million in Series A financing from Aisling Capital (New York) and Fidelity Biosciences (Boston). View Full Article
WuXi PharmaTech (NYSE:WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
October 29, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Dr. Ge Li, the company's Chairman and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year (EOY) China 2007 Award. View Full Article
WuXi PharmaTech (NYSE:WX) Ranked the 28th of Deloitte Technology Fast 50 China
October 26, 2007 - WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been ranked the 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. View Full Article
October 24, 2007 - Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and... View Full Article
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors
October 24, 2007 - Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and... View Full Article
October 17, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced progress on several key programs for addressing Alzheimer’s, Schizophrenia and Huntington’s diseases. View Full Article
EnVivo Announces Hiring of Chief Medical Officer
September 25, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced the appointment of Dr.Dana C. Hilt as Senior Vice President and Chief Medical Officer. View Full Article
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
September 17, 2007 - Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX), today announced that they have entered into a 50/50 partnership in the United States to co-develop and co-market Microbia’s first-in-class compound linaclotide. Linaclotide is currently being investigated... View Full Article
WuXi PharmaTech (NYSE:WX) Announces Closing of Initial Public Offering
August 14, 2007 - WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company in the growing global drug R&D outsourcing market, announced today the closing of its... View Full Article
FoldRX and Cystic Fibrosis Foundation Therapeutics Announce $22 Million Collaboration
August 13, 2007 - FoldRx Pharmaceuticals, Inc. (FoldRx) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today that FoldRx will receive up to $22 million over five years to discover and develop... View Full Article
July 12, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today the appointment of Nicholas G. Bacopoulos, Ph.D. to its Board of Directors. A 24-year industry veteran, Dr. Bacopoulos brings to Mersana extensive top-level management experience in the... View Full Article
BIOGEN IDEC AND CARDIOKINE PARTNER TO DEVELOP LIXIVAPTAN, A NOVEL VASOPRESSIN ANTAGONIST
July 2, 2007 - Biogen Idec (NASDAQ: BIIB) and Cardiokine, Inc., a privately-held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, today announced the signing of an agreement to jointly develop lixivaptan, an... View Full Article
U.S. Genomics Recognized for Outstanding Entrepreneurship by the National Science Foundation (NSF)
June 12, 2007 - U.S. Genomics Inc, a pioneer of single molecule biology technologies for the biodefense and life sciences industries, has been recognized by the NSF for outstanding entrepreneurship at its May NSF SBIR /STTR (Small Business Innovation Research/Small Business... View Full Article
Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors
May 30, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today that it has initiated a Phase I open-label, dose-escalation trial of its lead product candidate, XMT-1001, in patients with solid tumors. XMT-1001 is a polymer-based prodrug of... View Full Article
Microbia Announces Positive Phase 2 Results for its Investigational Compound Linaclotide
May 21, 2007 - Microbia today announced the presentation of data from a Phase 2 study in which linaclotide accelerated colonic transit and improved bowel function in patients with constipation-predominant irritable bowel syndrome (IBS-C). These data also showed... View Full Article
U. S. Genomics Awarded $8.6 Million for Phase III Bio-Defense Contract
May 15, 2007 - U.S. Genomics has been awarded an $8.6 million Phase III contract by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate to continue development of the Company's sophisticated biological sensor for biodefense applications. Under the... View Full Article
May 11, 2007 - Mersana Therapeutics, a cancer therapeutics company, announced today the appointment of Robert J. Fram, M.D., F.A.C.P. in the newly created position of Chief Medical Officer. Dr. Fram will oversee all clinical and medical activities at the company as it moves forward with... View Full Article
U.S. Genomics Appoints Salamone to Its Board of Directors
May 8, 2007 - U.S. Genomics announced today that Salvatore J. Salamone, Ph.D., has joined the company's Board of Directors. Dr. Salamone is presently also Chairman and Chief Executive Officer of Saladax BioMedical Inc., a developer of chemotherapy monitoring... View Full Article
April 13, 2007 - Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place... View Full Article
Bioconnect Systems Completes $8M Series A Financing
April 5, 2007 - (BUSINESS WIRE)--Bioconnect Systems, Inc. announced today that the company has raised $8 million in Series A financing. Bioconnect’s initial product platform, the Optiflow™, enables surgeons to create precisely controlled connections throughout the body. View Full Article
Intranasal Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran
April 4, 2007 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, today announced the appointment of Peter F. Young as President and Chief Executive Officer. Mr. Young was most recently the President and CEO of AlphaVax, a privately held biotechnology company based in Research Triangle Park, NC. He will be based in ITI’s corporate headquarters in Montvale, NJ. View Full Article
U.S. Genomics & The Biophysical Society Honor Howard C. Berg with Outstanding Investigator
March 5, 2007 - U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society's annual award for... View Full Article
U.S. Genomics & The Biophysical Society Honor Howard C. Berg with Outstanding Investigator
March 3, 2007 - U.S. Genomics announced today that Dr. Howard C. Berg, the Herchel Smith Professor of Physics the Professor of Molecular and Cellular Biology and a Member of the Rowland Institute at Harvard University, is the recipient of the Biophysical Society's annual award for... View Full Article
Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology
January 19, 2007 - In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation, Quest Diagnostics Incorporated (NYSE: DGX) today announced the signing of a worldwide license... View Full Article
U.S. Genomics and Northrop Grumman Sign Teaming Agreement
December 19, 2006 - U.S Genomics Inc. and the Northrop Grumman Corporation (NYSE: NOC) have signed a teaming agreement to work together to commercialize U.S. Genomics' single molecule detection technology. View Full Article
Intranasal Therapeutics, Inc. Adds Key Executives to Management Team
December 6, 2006 - Intranasal Therapeutics, Inc. (ITI), a specialty pharmaceutical company focused on developing nasally delivered, preservative-free drug products, announced today the appointment of two key executives to its management team. Franz F. Hefti, Ph.D., who has... View Full Article
Drug fights off disease but attracts investors
November 24, 2006 - Fledgling startup TetraPhase Pharmaceuticals Inc. has nailed down $25 million in a first round of venture financing toward developing treatments for drug-resistant infections. View Full Article
November 16, 2006 - MethylGene Inc. (TSX: MYG) with its collaborator EnVivo Pharmaceuticals, today announced that they have entered into a collaborative agreement with CHDI, Inc., a non-profit organization that is pursuing biotechnology approaches to rapidly discover and... View Full Article
EnVivo Pharmaceuticals Forms Research Collaboration With CHDI
October 25, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has established a research collaboration agreement with CHDI, Inc., a non-profit organization dedicated to... View Full Article
Linaclotide shown to improve symptoms of chronic constipation in phase 2A study
October 24, 2006 - Microbia today announced the presentation of data from a Phase 2a study demonstrating that treatment with linaclotide (MD-1100) improved bowel function in patients with chronic constipation. Treatment with linaclotide increased frequency of... View Full Article
U.S. Genomics and Lahey Clinic Announce Collaboration to Study the Role of microRNAs
October 17, 2006 - U.S Genomics Inc. and Lahey Clinic announce the signing of a discovery agreement to study the role microRNAs play in the development of urological cancers. The objective of the collaboration is to develop more accurate prognoses for bladder and... View Full Article
Envivo secures $24 million series C financing
October 4, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has secured $24 million in Series C financing led by existing investor Fidelity Biosciences. The company also said that... View Full Article
Transave, Inc. Appoints Renu Gupta, M.D. Chief Medical Officer
October 1, 2006 - Transave Inc., a biopharmaceutical company developing drugs for life-threatening lung diseases, today announced the appointment of Renu Gupta, M.D., as Executive Vice President of Development and Chief Medical Officer. View Full Article
August 2, 2006 - Transave, Inc., a biopharmaceutical company focused on the development of inhaled, liposomal formulation of drugs for treating life threatening lung diseases, today announced that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted... View Full Article
FoldRx Pharmaceuticals Closes $43 Million Series B Financing
May 30, 2006 - FoldRx Pharmaceuticals, Inc., a development-stage biotechnology company focused on protein misfolding diseases, announced today that it has successfully raised $43 million in a Series B financing. The funds will be used for the continued clinical development of... View Full Article
Envivo Expands Management Team As Company Prepares First Drugs For Clinical Trials
May 23, 2006 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has strengthened its management team with the appointment of Michael K. Ahlijanian, Ph.D. as Vice President, Research and... View Full Article
Microbia presents MD-1100 (Linaclotide Acetate) phase 1 results
May 23, 2006 - Microbia, Inc. today announced presentation of data from clinical and nonclinical studies with MD-1100 (linaclotide acetate), the Company’s first-in-class investigational drug for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic... View Full Article
Cardiokine, Inc. Closes $50 Million Series B Financing
May 1, 2006 - Cardiokine, Inc., a specialty pharmaceutical company focused on the development of drugs for the treatment and prevention of heart failure and related cardiovascular and metabolic indications, announced today the closing of a $50 million Series B preferred share equity offering. View Full Article
Transave, Inc. Appoints Donald Hayden, Jr. Executive Chairman Of Its Board Of Directors
April 28, 2006 - Transave Inc., a biopharmaceutical company developing inhaled liposomal formulated drugs for treating life threatening lung disease, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company's Board of Directors. Hayden is... View Full Article
Mersana Therapeutics, Inc. Appoints Key Members of Management Team
March 21, 2006 - Mersana, a privately-held cancer therapeutics company, announced today that Russell C. Petter, PhD, has joined the company as Vice President of Research and Ullrich S. Schwertschlag, MD, PhD as Vice President of Clinical Development. View Full Article
February 27, 2006 - Microbia, Inc., an entrepreneurial pharmaceutical company with two internally discovered drug candidates in clinical trials, today announced it has raised $75 million in a series E private equity financing. In addition, the company announced the initiation of... View Full Article
Mersana Therapeutics -- $21M Series B Co-led by Fidelity Biosciences
November 9, 2005 - Mersana, a privately-held cancer therapeutics company announced today that it has completed an oversubscribed $21 million financing. Fidelity Biosciences and ProQuest Investments led the round, with Rho Ventures and the company's previous investors participating, including... View Full Article
Envivo Appoints Kees Been As Chief Executive Officer
June 27, 2005 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing drugs for neurodegenerative diseases, announced today the appointment of Kees Been as Chief Executive Officer. View Full Article
1 Main Street, 13th Floor
Cambridge, MA 02142
Tel: (617) 231-2400
Fax: (617) 231-2425
Cambridge, MA 02142
Tel: (617) 231-2400
Fax: (617) 231-2425
Mailing Address
Fidelity Biosciences
82 Devonshire Street, EPC13A
Boston, MA 02109-3614
E-Mail: FidelityBiosciences@fmr.com
82 Devonshire Street, EPC13A
Boston, MA 02109-3614
E-Mail: FidelityBiosciences@fmr.com
© 2010 Fidelity Biosciences. All rights reserved.